| 1 |
Hu X, Wang L, Shang B, Wang J, Sun J, Liang B, Su L, You W, Jiang S. Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1094414] [Reference Citation Analysis]
|
| 2 |
Pang L, Xie M, Ma X, Huang A, Song J, Yao J, Deng H, Zhang D, Zang X, Ren F, Gao J, Wu C, Wang Y, Zhang X, Bao X, Pan L, Xue X. Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. BMC Cancer 2023;23:203. [PMID: 36869304 DOI: 10.1186/s12885-023-10649-0] [Reference Citation Analysis]
|
| 3 |
Tan P, Huang W, He X, Lv F, Cui Y, Du S. Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer. J Immunother 2023;46:64-73. [PMID: 36637978 DOI: 10.1097/CJI.0000000000000451] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Yu X, Wu J, Su C. Progress in diagnosis and treatment of checkpoint inhibitor pneumonitis. Curr Opin Oncol 2023;35:31-6. [PMID: 36322006 DOI: 10.1097/CCO.0000000000000909] [Reference Citation Analysis]
|
| 5 |
Wang W, Wang Q, Xu C, Li Z, Song Z, Zhang Y, Cai X, Zhang S, Lian B, Li W, Liu A, Zhan P, Liu H, Lv T, Miao L, Min L, Chen Y, Yuan J, Wang F, Jiang Z, Lin G, Pu X, Rao C, Lv D, Yu Z, Li X, Tang C, Zhou C, Xie C, Zhang J, Guo H, Chu Q, Meng R, Wu J, Zhang R, Wang L, Zhu Y, Hu X, Xie Y, Lin X, Cai J, Lan F, Feng H, Wang L, Yao W, Shi X, Huang J, Chen H, Zhang Y, Sun P, Wan B, Pang F, Xu Z, Wang K, Xia Y, Ye M, Wang D, Wei Q, Feng S, Zhou J, Zhang J, Lv D, Gao W, Kang J, Yu G, Liang X, Yu C, Shi L, Yang N, Wu L, Hong Z, Hong W, Fang M, Zhang Y, Lu Y, Wang G, Ma S, Si L, Fang W, Song Y. Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor. Thorac Cancer 2022;13:3420-30. [PMID: 36268845 DOI: 10.1111/1759-7714.14693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Pang L, Xie M, Ma X, Huang A, Song J, Yao J, Deng H, Zhang D, Zang X, Ren F, Gao J, Wu C, Wang Y, Zhang X, Bao X, Pan L, Xue X. Clinical Characteristics and Therapeutic Effects of Checkpoint Inhibitor-Related Pneumonitis in Patients with Non-Small Cell Lung Cancer.. [DOI: 10.21203/rs.3.rs-2174785/v1] [Reference Citation Analysis]
|
| 7 |
Li X, Lv F, Wang Y, Du Z. Establishment and validation of nomogram for predicting immuno checkpoint inhibitor related pneumonia. BMC Pulm Med 2022;22:331. [PMID: 36050683 DOI: 10.1186/s12890-022-02127-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Xie X, Wang L, Li Y, Xu Y, Wu J, Lin X, Lin W, Mai Q, Chen Z, Zhang J, Xie Z, Qin Y, Liu M, Lu M, Luo B, Zhou C. Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study. Front Immunol 2022;13:879900. [DOI: 10.3389/fimmu.2022.879900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 9 |
Qiu Q, Xing L, Wang Y, Feng A, Wen Q. Development and Validation of a Radiomics Nomogram Using Computed Tomography for Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis From Radiation Pneumonitis for Patients With Non-Small Cell Lung Cancer. Front Immunol 2022;13:870842. [PMID: 35558076 DOI: 10.3389/fimmu.2022.870842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Yin J, Wu Y, Yang X, Gan L, Xue J. Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism. Front Immunol 2022;13:830631. [PMID: 35464480 DOI: 10.3389/fimmu.2022.830631] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 11 |
Huang L, Jiang S, Shi Y. Prognostic significance of baseline neutrophil-lymphocyte ratio in patients with non-small-cell lung cancer: a pooled analysis of open phase III clinical trial data. Future Oncol 2022. [PMID: 35132871 DOI: 10.2217/fon-2021-1304] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
